NEXTGENPCR: 30 cycli, 3 temperatures, less than 2 minutes



Leading diagnostics laboratory in the Caribbean selects NextGenPCR for SARS-CoV-2 testing

Clinical implementation of ultra-fast molecular testing improves time to result and laboratory throughput


Goes, Netherlands, March 31, 2021 — Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba’s Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing. With a single NextGenPCR system capable of producing over 1,000 results per day, Laboratorio di Servicio has ensured they have capacity beyond their current 300 test results per day.


“Last January, our lab Laboratorio di Servicio implemented the MBS’ NextGenPCR solution for CoV2 screening, on Aruba.” says Director of Clinical Chemistry at LdS, Robert Wever. “We found this ultra-fast PCR technology easy to use, sensitive, specific and overall, really ultra-fast, both in throughput as well as time to result.”


MBS has advanced the readout methodology first described last year in collaboration with the University of Bielefeld, to also be compatible with multi-color PCR assays that can monitor additional viral targets and process controls present in clinical diagnostic assays. Labs using ultra-fast RT-PCR in combination with proven SARS-CoV-2 tests and direct from sample RT-PCR has resulted in more than doubling their testing capacity.


“Throughout, labs have wanted to deliver more by increasing the efficiency of their workflow” says MBS CEO and founder, Gert de Vos. “So, Laboratorio di Servicio is just one example of how NextGenPCR has delivered higher throughput by reducing time spent on RT-PCR.”


Find out more at


About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a life sciences solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.


About Laboratorio di Servicio N.V.

Laboratorio di Servicio N.V (LdS), formerly Service Lab Xpert, started delivering laboratory services to Aruba in August 2012. The focus of LdS is primary care, services to medical specialists, institutions, veterinary practices and private companies. LdS offers different clinical tests for allergy, diabetes, anemia, cancer, drug abuse, thyroid, pregnancy, the digestive system and more.


All referenced product names, and other marks, are trademarks of their respective owners.
© 2021 Molecular Biology Systems, B.V. All rights reserved.



Media contact:

Brian McNally, PhD
Molecular Biology Systems B.V.

+1 301.366.1083

Ultrafast RT-PCR for COVID-19 by Molecular Biology Systems draws Dutch government support

Publication demonstrates updated NEXTGENPCR accelerates detection of SARS-CoV-2 RNA from clinical samples


Goes, Netherlands, April 2, 2020 – Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test for SARS-CoV-2 with a one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled ” Ultra-fast one-step RT-PCR protocol for the detection of SARS-CoV-2,” has been submitted as a preprint is available here:


“We immediately started with a COVID-19 diagnostic project, since we already got a NEXTGENPCR thermocycler for sepsis diagnostics. Using this technology, we demonstrated with clinical RNA isolates, the ability to dramatically increase SARS-CoV-2 testing throughput without a loss in sensitivity.” says Prof. Dr. Christian Kaltschmidt, Cell Biology of the University of Bielefeld, the senior author of the publication.


MBS has developed and released two software packages that result in a streamlined workflow from isolated nucleic acid sample to result. First, the machine’s operating system has been updated with two enabling features, onboard reverse transcription and 2-step PCR. These features decrease the number of handling steps, and plate shuttling time which together result in an improved, shorter protocol. The second software package automates the measurement and analysis of endpoint fluorescence, allowing users to automate calls based on predetermined thresholds.


“After accelerating the CDC assay, we received a lot of positive feedback.” says MBS CEO and founder, Gert de Vos. “We added software, tested more WHO-recommended protocols and have collaborated with labs to deliver a demonstration of ultrafast RT-PCR for SARS-CoV-2.”


To support companies responding to COVID-19, the Dutch government has awarded funds to MBS. Rosco Efraïm, Project Manager Impuls Zeeland, stated “MBS demonstrated a clear contribution to the advancement of SARS-CoV-2 testing both locally and globally, so the government awarded these funds to ensure this innovative company executes its mission.”


With a single NEXTGENPCR system delivering over 570 test results per hour, MBS is now collaborating with government and private testing laboratories in the USA, Europe, the Middle East and Africa to implement this method.


Find out more at


About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.


All referenced product names, and other marks, are trademarks of their respective owners.

© 2020 Molecular Biology Systems, B.V. All rights reserved.



Media contact:

Brian McNally, PhD
Molecular Biology Systems B.V.

+1 301.366.1083

Dutch Firm Molecular Biology Systems Validating Rapid Thermal Cycler for COVID-19 Testing

NEW YORK – Dutch company Molecular Biology Systems is in the process of validating its shoebox-sized NextGenPCR instrument for rapid SARS-CoV-2 diagnostic testing, claiming the system could potentially process more than 22,000 samples in a day by performing plate-based thermal cycling in less than eight minutes.

Research-use only instruments are now being recruited for SARS-CoV-2 testing under rapidly changing regulatory guidelines worldwide. US Food and Drug Administration guidance, for example, has evolved to specify that that test developers are allowed to create Emergency Use Authorized workflows on instruments that have not yet been cleared for diagnostic testing.

Gert de Vos, CEO and founder of MBS, said in an interview that similar guidance is now being issued in Europe for RUO instruments.

“The world has changed completely,” de Vos said. High-complexity labs are eminently qualified to do the required validation testing to verify RUO instruments, he added.

The NextGenPCR system can perform 30-cycle PCR in two minutes, de Vos said.

The instrument contains six blocks with three fixed temperatures. Sealed microwell plates containing the reagents are shuttled between temperatures for thermal cycling. This obviates the temperature ramping required with a standard thermal cycling block because temperature changes on NextGenPCR takes a tenth of a second, de Vos said.

The system uses its own consumable plates, which are the size and shape of standard 384-well plates with a very different middle section featuring a polypropylene sheet with indentations to create the wells. These plates come in 5-µl and 20-µl 96-well formats, but the firm has also developed a 384-well plate for the instrument that can be used with volumes from 2 µl to 5 µl.

Aliquoting sample to the plate can be done manually or with a robotic liquid-handling system, as the wells are in the same positions as standard 96- and 384-well plates.

When MBS learned that RUO instruments could be used for COVID-19 testing, the firm used the fast turnaround time of its platform to its advantage, obtaining reagents from Integrated DNA Technologies overnight and performing about 1,000 PCR runs in a few days.

The firm has now been working on SARS-CoV-2 testing for about one month.

It has run a dilution series of virus-containing plasmids from Integrated DNA Technologies on the NextGenPCR instrument and on a Bio-Rad CFX qPCR system. In the MBS lab, the limit of detection of the CDC kit on the Bio-Rad platform was 10 positive plasmid particles per sample, de Vos said, while the NextGenPCR system could detect down to one plasmid per sample. “It’s safe to say that we are at least as sensitive as a standard real-time cycler,” he said.

The NextGenPCR system is endpoint PCR, and the firm has validated it with the US Centers for Disease Control and Prevention protocol to perform 40 cycles in less than eight minutes. The reverse transcription step can be done outside the system, or on the instrument, de Vos said.

In addition, in a research evaluation of the NextGenPCR instrument published in The Journal of Microbiological Methods in February, a group at The University of Groningen found equivalent sensitivity compared to a standard thermal cycler, the Eppendorf Mastercycler Nexus PCR instrument.

The group was evaluating the MBS NextGenPCR instrument for detection of E. coli strains that cause urinary tract infections, so was looking for bacterial DNA in urine samples. It adapted a fast extraction method to take only 5 minutes.

The technique was then validated on 128 clinical urine samples from patients with UTIs, and all target gene regions were amplified similarly across the two machines. Amplification in the standard thermal cycler took more than three times longer than with the NextGenPCR instrument, however.

Jolanda Brons, the first author of the JMM study, commented in an email that overall the instrument “turned out to be just as good as a regular thermal cycler,” but with the benefit performing a run in a much shorter time period.

“Our research paper showed that this machine is very fast and accurate, [and] we believe it can be a very reliable machine in the detection of COVID-19,” she said.

Endpoint benefits

The original rationale for using quantitative PCR testing for COVID-19 is unclear, although there may be some indication that people with higher viral loads can have more severe illness. But for simply finding positive cases, endpoint PCR could be sufficient, de Vos said. The MBS instrument could also theoretically be used upfront, to quickly find positive cases, which could then be quantitated if needed.

Extraction could be a rate-limiting step in a rapid testing workflow, but de Vos said there are rapid sample preparation methods that take around five minutes. These essentially perform a lysis step and do not concentrate the RNA, “But in an endpoint PCR, that is not really necessary – it’s all about ‘Is it positive or negative?'”

The samples are sealed in the plate with a clear film, and because the CDC kit uses a fluorescent dye, a virus-positive well will light up.

The fact that the CDC test is not multiplexed may mean more pipetting is required per sample, but this also enables using a scanner to read out results, which obviates the need to run a gel, de Vos suggested.

“We simply take the plate out of our system and put it upside-down on a gel scanner, and that’s it – in a few seconds you have your answer,” de Vos said.

The CDC test requires three wells per patient sample, so using that assay an MBS 384-well plate can process 127 samples in a plate, in less than 8 minutes. Thus, in 24 hours the system can theoretically process 22,860 patient samples, de Vos said. This throughput can scale up, such that with 10 instruments, it would be possible to test a quarter of a million people a day, he added.

It can also be scaled down to run a single test, for example to run testing to mitigate exposures in other hospital procedures, like surgeries, de Vos said.

MBS is also evaluating a testing method that uses a single viral target based on an open-source protocol developed in the Czech Republic, de Vos said. This assay could be run with a single control in a plate, expanding the capacity to 383 patient samples per 8-minute run.

The company is also testing out other enzymes and reagents, including a colorimetric version of the assay which could be visually read.

“Any lab that has our system can do their own validation, and because the PCR doesn’t take 90 minutes but seven-and-a-half minutes, the validation doesn’t take a week, but instead takes a few days,” de Vos said, adding,

There are now several labs in Europe and the US validating the MBS NextGenPCR system for COVID-19 testing, de Vos said, but he declined to name them at this time. And, the firm has also been working on modifying the system to enable running real-time PCR as well.

The firm has also had a few recent business developments. It hired Ronald Burggrave as business development director for Europe, the Middle East, and Africa, and it brought on Brian McNally as chief commercial officer in November last year. McNally is based in the US, and de Vos noted that the MBS instrument is distributed in the US by Velocidy Bio.

The firm currently counts sequencing platform developers and forensics firms among its customers, de Vos said, but he was not at liberty to name them.

Manufacturing capacity has been a bottleneck for other companies during the COVID-19 pandemic, but de Vos doesn’t think MBS will have any issues. The company has approximately 30 instruments in stock and 100 on the way in the coming two weeks, he said. It could also manufacture up to 500 more in the next six weeks, and has an ample stock of consumables.

“As soon as we saw this coming, we started making plates in double shifts,” he said.

Molecular Biology Systems accelerates CDC-designed assay while alleviating consumable demand


Goes, Netherlands, March 31, 2020 — Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost ten-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. Detection of amplified product can be done with widely-available blue light gel document systems.


“We sought to decrease what we identified as the longest step in the current testing scheme, amplification.” says MBS CEO and founder, Gert de Vos. “We started with the CDC assay because it is well characterized and has been readily available.”


Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, MBS tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require twenty-five percent of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol.


NEXTGENPCR machines launched about two years ago and are available globally. Gert de Vos stated “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with 8-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”


MBS is now collaborating with testing laboratories in the USA and the Netherlands to transfer and validate the method.


Find out more at


About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.


All referenced product names, and other marks, are trademarks of their respective owners.

© 2020 Molecular Biology Systems, B.V. All rights reserved.





Molecular Biology Systems and Velocidy Bio sign distribution agreement.

NEXTGENPCR, the ultrafast PCR system, is now available in the United States and Canada.

Goes, Netherlands, Feb. 19, 2020

Molecular Biology Systems (MBS), the developer of NEXTGENPCR, is pleased to announce their newest distributor, Velocidy Bio. Velocidy Bio becomes the exclusive distributor of NEXTGENPCR instruments, accessories and consumables in the United States and Canada. NEXTGENPCR is an innovative thermal cycler that can reduce cycling programs to less than two minutes, by both eliminating ramp times as well as reducing dwell times.

“NEXTGENPCR is an innovative solution that accelerates nucleic acid amplification, so we identify special commercial partners that will support users as they adopt our system.” states Gert de Vos, Founder and CEO of Molecular Biology Systems. “We look forward to working with Velocidy Bio, an innovative distributor focused on improving the laboratory experience by accelerating protocols.”

The NEXTGENPCR’s design does not disrupt current laboratory workflows, instead it accelerates the cycling protocol. Therefore, the NEXTGENPCR system has been widely adopted across laboratory segments including public and private research and testing labs in academia, government, biotech and pharmaceutical. Since launching two years ago, MBS has increasing the rate of NEXTGENPCR placements.

The NEXTENPCR instrument, accessories, and consumables are now available in the United States and Canada for purchase through Velocidy Bio at For other countries, please see Molecular Biology Systems’ commercial partners at

About Molecular Biology Systems

Molecular Biology Systems B.V. is a Netherlands company that developed and commercialized NEXTGENPCR, a universal ultrafast PCR system. The NEXTENPCR instrument uses an innovative temperature control method during cycling, which eliminates ramp time. Molecular Biology Systems offers their NEXTGENPCR instrument, accessories and consumables around the world, to laboratories in life science research, pharmaceutical and biotechnology companies, forensics, veterinary testing and food safety. Further information can be found at

About Velocidy Bio, Inc.

Velocidy Bio is focused on delivering solutions that decrease time-to-results for biological laboratories. Working together with innovative organizations, Velocidy Bio offers solutions globally that reduce protocols from hours to minutes. These accelerated protocols enable scientists to increase their productivity and reduce stress associated with delays in generating results.  Initially, Velocidy Bio is focused on reducing the time required to extract, amplify and analyze nucleic acids. Further information can be found at


See 2 minute PCR at the ASHG

Molecular Biology Systems will be exhibiting at this year’s American Society of Human Genetics Conference from October 15-19, 2019 in Houston, USA. MBS is looking forward to meeting those attending. To learn more about NextGenPCR, stop by Booth 107 any time during the exhibit.

MBS introduces NextGenPCR. Using SBS-plate format a 100bp fragment can be amplified in 2 minutes (30 cycles, 3 temperatures). Longer fragments take slightly longer, but will still be amplified in minutes rather than hours. This versatile system lets you run 96-well plates and 384-well plates without changing blocks. Volumes range from 3 to 50 microliters. The technology has proven to work over a wide range of application.

For more information about American Society of Human Genetics Conference 2019, visit their website.

We hope to see you in Houston, USA!